https://orcid.org/0000-0003-4721-2695
Pretransplant single dose CD45-ADC conditioning effectively promoted alloengraftment with low toxicity in 3 FA mouse models.
Acute GVHD induced by donor T cells was significantly less in CD45-ADC vs lethal irradiation conditioned wild-type or Fanca−/− recipients.
Abstract
Fanconi anemia (FA) is an inherited DNA repair disorder characterized by bone marrow (BM) failure, developmental abnormalities, myelodysplasia, leukemia, and solid tumor predisposition. Allogeneic hematopoietic stem cell transplantation (allo-HSCT), a mainstay treatment, is limited by conditioning regimen–related toxicity and graft-versus-host disease (GVHD). Antibody-drug conjugates (ADCs) targeting hematopoietic stem cells (HSCs) can open marrow niches permitting donor stem cell alloengraftment. Here, we report that single dose anti-mouse CD45–targeted ADC (CD45-ADC) facilitated stable, multilineage chimerism in 3 distinct FA mouse models representing 90% of FA complementation groups. CD45-ADC profoundly depleted host stem cell enriched Lineage−Sca1+cKit+ cells within 48 hours. Fanca−/− recipients of minor-mismatched BM and single dose CD45-ADC had peripheral blood (PB) mean donor chimerism >90%; donor HSCs alloengraftment was verified in secondary recipients. In Fancc−/− and Fancg−/− recipients of fully allogeneic grafts, PB mean donor chimerism was 60% to 80% and 70% to 80%, respectively. The mean percent donor chimerism in BM and spleen mirrored PB results. CD45-ADC–conditioned mice did not have clinical toxicity. A transient <2.5-fold increase in hepatocellular enzymes and mild-to-moderate histopathological changes were seen. Under GVHD allo-HSCT conditions, wild-type and Fanca−/− recipients of CD45-ADC had markedly reduced GVHD lethality compared with lethal irradiation. Moreover, single dose anti–human CD45-ADC given to rhesus macaque nonhuman primates on days −6 or −10 was at least as myeloablative as lethal irradiation. These data suggest that CD45-ADC can potently promote donor alloengraftment and hematopoiesis without significant toxicity or severe GVHD, as seen with lethal irradiation, providing strong support for clinical trial considerations in highly vulnerable patients with FA.
References
1.
Bagby
GC
. Genetic basis of Fanconi anemia
. Curr Opin Hematol
. 2003
;10
(1
):68
-76
.2.
Kook
H
. Fanconi anemia: current management
. Hematology
. 2005
;10
(suppl 1
):108
-110
.3.
Mathew
CG
. Fanconi anemia genes and susceptibility to cancer
. Oncogene
. 2006
;25
(43
):5875
-5884
.4.
Ceccaldi
R
, Sarangi
P
, D’Andrea
AD
. The Fanconi anemia pathway: new players and new functions
. Nat Rev Mol Cell Biol
. 2016
;17
(6
):337
-349
.5.
Taniguchi
T
, D’Andrea
AD
. Molecular pathogenesis of Fanconi anemia: recent progress
. Blood
. 2006
;107
(11
):4223
-4233
.6.
van Twest
S
, Murphy
VJ
, Hodson
C
, et al. Mechanism of ubiquitination and deubiquitination in the Fanconi anemia pathway
. Mol Cell
. 2017
;65
(2
):247
-259
.7.
Dong
H
, Nebert
DW
, Bruford
EA
, Thompson
DC
, Joenje
H
, Vasiliou
V
. Update of the human and mouse Fanconi anemia genes
. Hum Genomics
. 2015
;9
:32
.8.
Nalepa
G
, Clapp
DW
. Fanconi anaemia and cancer: an intricate relationship
. Nat Rev Cancer
. 2018
;18
(3
):168
-185
.9.
Gluckman
E
, Broxmeyer
HA
, Auerbach
AD
, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling
. N Engl J Med
. 1989
;321
(17
):1174
-1178
.10.
Broxmeyer
HE
, Douglas
GW
, Hangoc
G
, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells
. Proc Natl Acad Sci U S A
. 1989
;86
(10
):3828
-3832
.11.
Rio
P
, Navarro
S
, Wang
W
, et al. Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia
. Nat Med
. 2019
;25
(9
):1396
-1401
.12.
Kutler
DI
, Singh
B
, Satagopan
J
, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR)
. Blood
. 2003
;101
(4
):1249
-1256
.13.
Kelly
PF
, Radtke
S
, von Kalle
C
, et al. Stem cell collection and gene transfer in Fanconi anemia
. Mol Ther
. 2007
;15
(1
):211
-219
.14.
Ceccaldi
R
, Parmar
K
, Mouly
E
, et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells
. Cell Stem Cell
. 2012
;11
(1
):36
-49
.15.
Haneline
LS
, Gobbett
TA
, Ramani
R
, et al. Loss of FancC function results in decreased hematopoietic stem cell repopulation ability
. Blood
. 1999
;94
(1
):1
-8
.16.
Haneline
LS
, Li
X
, Ciccone
SL
, et al. Retroviral-mediated expression of recombinant Fancc enhances the repopulation ability of Fancc-/- hematopoietic stem cells and decreases the risk of clonal evolution
. Blood
. 2003
;101
(4
):1299
-1307
.17.
Cumming
RC
, Lightfoot
J
, Beard
K
, Youssoufian
H
, O’Brien
PJ
, Buchwald
M
. Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1
. Nat Med
. 2001
;7
(7
):814
-820
.18.
Hadjur
S
, Ung
K
, Wadsworth
L
, et al. Defective hematopoiesis and hepatic steatosis in mice with combined deficiencies of the genes encoding Fancc and Cu/Zn superoxide dismutase
. Blood
. 2001
;98
(4
):1003
-1011
.19.
Saadatzadeh
MR
, Bijangi-Vishehsaraei
K
, Hong
P
, Bergmann
H
, Haneline
LS
. Oxidant hypersensitivity of Fanconi anemia type C-deficient cells is dependent on a redox-regulated apoptotic pathway
. J Biol Chem
. 2004
;279
(16
):16805
-16812
.20.
Li
H
, Xu
Q
. A successful second stem cell transplantation in Fanconi anemia: a case report
. Transplant Proc
. 2015
;47
(7
):2298
-2300
.21.
Vincent
CL
, Primack
WA
, Hipps
J
, Kasow
KA
. Sequential renal and bone marrow transplants in a child with Fanconi anemia
. Pediatr Transplant
. 2016
;20
(1
):146
-150
.22.
MacMillan
ML
, Hughes
MR
, Agarwal
S
, Daley
GQ
. Cellular therapy for Fanconi anemia: the past, present, and future
. Biol Blood Marrow Transplant
. 2011
;17
(1 suppl
):S109
-114
.23.
MacMillan
ML
, DeFor
TE
, Young
JA
, et al. Alternative donor hematopoietic cell transplantation for Fanconi anemia
. Blood
. 2015
;125
(24
):3798
-3804
.24.
Bonfim
C
, Ribeiro
L
, Nichele
S
, et al. Long-term survival, organ function, and malignancy after hematopoietic stem cell transplantation for Fanconi anemia
. Biol Blood Marrow Transplant
. 2016
;22
(7
):1257
-1263
.25.
Peffault de Latour
R
, Porcher
R
, Dalle
JH
, et al; FA Committee of the Severe Aplastic Anemia Working Party
Pediatric Working Party of the European Group for Blood and Marrow Transplantation
. Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience
. Blood
. 2013
;122
(26
):4279
-4286
.26.
Anur
P
, Friedman
DN
, Sklar
C
, et al. Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors
. Bone Marrow Transplant
. 2016
;51
(7
):938
-944
.27.
Rosenberg
PS
, Greene
MH
, Alter
BP
. Cancer incidence in persons with Fanconi anemia
. Blood
. 2003
;101
(3
):822
-826
.28.
Kutler
DI
, Auerbach
AD
, Satagopan
J
, et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia
. Arch Otolaryngol Head Neck Surg
. 2003
;129
(1
):106
-112
.29.
Saha
A
, Blazar
BR
. Antibody based conditioning for allogeneic hematopoietic stem cell transplantation
. Front Immunol
. 2022
;13
:1031334
.30.
Saha
A
, Hyzy
S
, Lamothe
T
, et al. A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice
. Blood
. 2022
;139
(11
):1743
-1759
.31.
Cheng
NC
, van de Vrugt
HJ
, van der Valk
MA
, et al. Mice with a targeted disruption of the Fanconi anemia homolog Fanca
. Hum Mol Genet
. 2000
;9
(12
):1805
-1811
.32.
Rio
P
, Segovia
JC
, Hanenberg
H
, et al. In vitro phenotypic correction of hematopoietic progenitors from Fanconi anemia group A knockout mice
. Blood
. 2002
;100
(6
):2032
-2039
.33.
Wulf
GG
, Luo
KL
, Goodell
MA
, Brenner
MK
. Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation
. Blood
. 2003
;101
(6
):2434
-2439
.34.
Chen
M
, Tomkins
DJ
, Auerbach
W
, et al. Inactivation of Fac in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconi anaemia
. Nat Genet
. 1996
;12
(4
):448
-451
.35.
Parmar
K
, D’Andrea
A
, Niedernhofer
LJ
. Mouse models of Fanconi anemia
. Mutat Res
. 2009
;668
(1-2
):133
-140
.36.
Pulliam-Leath
AC
, Ciccone
SL
, Nalepa
G
, et al. Genetic disruption of both Fancc and Fancg in mice recapitulates the hematopoietic manifestations of Fanconi anemia
. Blood
. 2010
;116
(16
):2915
-2920
.37.
Yang
Y
, Kuang
Y
, Montes De Oca
R
, et al. Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9
. Blood
. 2001
;98
(12
):3435
-3440
.38.
Koomen
M
, Cheng
NC
, van de Vrugt
HJ
, et al. Reduced fertility and hypersensitivity to mitomycin C characterize Fancg/Xrcc9 null mice
. Hum Mol Genet
. 2002
;11
(3
):273
-281
.39.
Parker
DC
, Greiner
DL
, Phillips
NE
, et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand
. Proc Natl Acad Sci U S A
. 1995
;92
(21
):9560
-9564
.40.
Larsen
CP
, Elwood
ET
, Alexander
DZ
, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
. Nature
. 1996
;381
(6581
):434
-438
.41.
Blazar
BR
, Taylor
PA
, Panoskaltsis-Mortari
A
, et al. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation
. J Immunol
. 1997
;158
(1
):29
-39
.42.
Durham
MM
, Bingaman
AW
, Adams
AB
, et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor specific tolerance without cytoreductive conditioning
. J Immunol
. 2000
;165
(1
):1
-4
.43.
Taylor
PA
, Lees
CJ
, Waldmann
H
, Noelle
RJ
, Blazar
BR
. Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions
. Blood
. 2001
;98
(2
):467
-474
.44.
Taylor
PA
, Lees
CJ
, Wilson
JM
, et al. Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions
. Blood
. 2002
;100
(9
):3400
-3407
.45.
Hermiston
ML
, Xu
Z
, Weiss
A
. CD45: a critical regulator of signaling thresholds in immune cells
. Annu Rev Immunol
. 2003
;21
:107
-137
.46.
Dahlke
MH
, Larsen
SR
, Rasko
JE
, Schlitt
HJ
. The biology of CD45 and its use as a therapeutic target
. Leuk Lymphoma
. 2004
;45
(2
):229
-236
.47.
Bergamaschi
G
, Perfetti
V
, Tonon
L
, et al. Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis
. Br J Haematol
. 1996
;93
(4
):789
-794
.48.
Srikanthan
MA
, Humbert
O
, Haworth
KG
, et al. Effective multi-lineage engraftment in a mouse model of Fanconi anemia using non- genotoxic antibody-based conditioning
. Mol Ther Methods Clin Dev
. 2020
;17
:455
-464
.49.
Hill
GR
, Betts
BC
, Tkachev
V
, Kean
LS
, Blazar
BR
. Current concepts and advances in graft-versus-host disease immunology
. Annu Rev Immunol
. 2021
;39
:19
-49
.50.
Shlomchik
WD
, Couzens
MS
, Tang
CB
, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells
. Science
. 1999
;285
(5426
):412
-415
.51.
Koyama
M
, Hill
GR
. The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease
. Blood
. 2019
;134
(24
):2139
-2148
.52.
Persaud
SP
, Ritchey
JK
, Kim
S
, et al. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation
. J Clin Invest
. 2021
;131
(24
):e145501
.53.
Okada
S
, Nakauchi
H
, Nagayoshi
K
, et al. Enrichment and characterization of murine hematopoietic stem cells that express c-kit molecule
. Blood
. 1991
;78
(7
):1706
-1712
.54.
Domen
J
, Weissman
IL
. Hematopoietic stem cells need two signals to prevent apoptosis; BCL-2 can provide one of these, kitl/c-kit signaling the other
. J Exp Med
. 2000
;192
(12
):1707
-1718
.55.
Kent
D
, Copley
M
, Benz
C
, Dykstra
B
, Bowie
M
, Eaves
C
. Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway
. Clin Cancer Res
. 2008
;14
(7
):1926
-1930
.56.
Chandrakasan
S
, Jayavaradhan
R
, Ernst
J
, et al. KIT blockade is sufficient for donor hematopoietic stem cell engraftment in Fanconi anemia mice
. Blood
. 2017
;129
(8
):1048
-1052
.57.
Miettinen
M
, Lasota
J
. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation
. Appl Immunohistochem Mol Morphol
. 2005
;13
(3
):205
-220
.58.
Rathbun
RK
, Faulkner
GR
, Ostroski
MH
, et al. Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells
. Blood
. 1997
;90
(3
):974
-985
.59.
Zhang
X
, Li
J
, Sejas
DP
, Rathbun
KR
, Bagby
GC
, Pang
Q
. The Fanconi anemia proteins functionally interact with the protein kinase regulated by RNA (PKR)
. J Biol Chem
. 2004
;279
(42
):43910
-43919
.60.
Bijangi-Vishehsaraei
K
, Saadatzadeh
MR
, Werne
A
, et al. Enhanced TNF-alpha-induced apoptosis in Fanconi anemia type C-deficient cells is dependent on apoptosis signal-regulating kinase 1
. Blood
. 2005
;106
(13
):4124
-4130
.61.
Si
Y
, Ciccone
S
, Yang
FC
, et al. Continuous in vivo infusion of interferon-gamma (IFN-gamma) enhances engraftment of syngeneic wild-type cells in Fancc-/- and Fancg-/- mice
. Blood
. 2006
;108
(13
):4283
-4287
.62.
Li
J
, Sejas
DP
, Zhang
X
, et al. TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells
. J Clin Invest
. 2007
;117
(11
):3283
-3295
.© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2024
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal